GMAB News and Press, Genmab A/S From 06/06/24

2024-06-06 12:51:08 ET More on Halozyme Therapeutics Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript Halozyme Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics ...

2024-06-04 10:00:04 ET Asthika Goonewardene from Truist Financial issued a price target of $53.00 for GMAB on 2024-06-04 08:14:00. The adjusted price target was set to $53.00. At the time of the announcement, GMAB was trading at $28.83. The overall price target consensus...

Results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate in patients with recurrent or metastatic HNSCC, presented in a rapid oral session at 2024 ASCO ® Annual Meeting HNSCC is the sixth most common cancer worldwide, with inciden...

Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with rituximab-lenalidomide (R 2 ) experienced a 95% overall response rate (ORR) Results from the optimizat...

2024-06-01 13:30:00 ET More on BioNTech BioNTech SE 2024 Q1 - Results - Earnings Call Presentation BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript BioNTech: Undecided Between A One Trick Pony And A Full-Fledged Pharma Company BioNTech gains antibody drug ...

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of 17.5 months in patients with previously treated PD-L1-positive mNSCLC treated with combination of acasunlimab with pembrolizumab every six weeks Data from t...

Six oral and poster presentations will highlight breadth of clinical program and potential utility of epcoritamab-bysp in patients with difficult-to-treat lymphomas across multiple lines of therapy and histologies where high unmet needs exist Results from two studies evaluating tisotumab ...

Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate technology platforms ...

Sixteen abstracts accepted for presentation and publication demonstrate depth and breadth of comprehensive epcoritamab development program Three oral presentations highlight novel data evaluating epcoritamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL), in combinati...

2024-05-11 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...